Ocular Therapeutix (OCUL) FCF Margin (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly FCF Margin of 524.22% for Q2 2026, down 10456.0% year-over-year from N/an in Q2 2025, and up 19.98% on a QoQ basis from 655.12% in Q1 2026.
Ocular Therapeutix (OCUL) FCF Margin (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported FCF Margin for 13 years, with the latest figure at 524.22% in Q2 2026.
- FCF Margin for Q2 2026 came in at 524.22%, down 10456.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 490.07% (down 17352.0% YoY), and the FY2025 annual result was 417.5%, down 20413.0% from the prior year.
- FCF Margin advanced to 524.22% in Q2 2026, from 655.12% in the prior quarter.
- Over five years, FCF Margin peaked at 52.99% in Q3 2023 and troughed at 655.12% in Q1 2026.
- A 5-year average of 262.65% and a median of 203.31% in 2024 frame the typical range for FCF Margin.
- The widest annual swing landed in 2022, when FCF Margin jumped 9545 bps; it then tumbled 26513 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 135.76% in 2022, then decreased by 14 bps to 154.81% in 2023, then slumped by 50 bps to 232.0% in 2024, then slumped by 86 bps to 430.85% in 2025, then declined by 22 bps to 524.22% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 524.22% in Q2 2026, 655.12% in Q1 2026, and 430.85% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -524.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -524.22% |
| Mar 31, 2026 | -624.20% |
| Dec 31, 2025 | -430.85% |
| Sep 30, 2025 | -389.98% |
| Jun 30, 2025 | -419.67% |
| Mar 31, 2025 | -435.63% |
| Dec 31, 2024 | -231.09% |
| Sep 30, 2024 | -237.23% |
| Jun 30, 2024 | -149.57% |
| Mar 31, 2024 | -231.10% |
| Dec 31, 2023 | -191.03% |
| Sep 30, 2023 | -17.44% |
| Jun 30, 2023 | -145.30% |
| Mar 31, 2023 | -174.61% |
| Dec 31, 2022 | -126.93% |
| Sep 30, 2022 | -112.00% |
| Jun 30, 2022 | -89.66% |
| Mar 31, 2022 | -141.98% |
| Dec 31, 2021 | -122.97% |
| Sep 30, 2021 | -106.10% |